grant
Bromodomain and extra-terminal motif (BET) inhibitors in Solitary fibrous tumor (SFT)
Organization UNIVERSITY OF TEXAS DALLASLocation RICHARDSON, UNITED STATESPosted 1 Apr 2024Deadline 31 Mar 2029
NIHUS FederalResearch GrantFY202621+ years oldAdultAdult HumanAdverse effectsAnatomic SitesAnatomic structuresAnatomyAngiogenesis AntagonistsAngiogenesis BlockersAngiogenesis InhibitorsAngiogenetic AntagonistsAngiogenetic InhibitorsAngiogenic AntagonistsAngiogenic InhibitorsAngiostatic AgentsAnimal ModelAnimal Models and Related StudiesAnti-Angiogenetic AgentsAnti-Angiogenic AgentsAnti-Angiogenic DrugsAntiangiogenesis AgentsAntiangiogenic AgentsAntiangiogenic DrugsAreaAssayBET bromodomain inhibitorBET inhibitorBETiBindingBioassayBiological AssayBiological MarkersBiomedical EngineeringBlood VesselsBromodomainBromodomain and Extra-Terminal motif inhibitorBromodomains and extra-terminal domain inhibitorCNS Nervous SystemCRISPRCRISPR/Cas systemCancer BiologyCancer CenterCancersCell modelCellular modelCentral Nervous SystemCharacteristicsChemotherapy ProtocolChemotherapy RegimenChemotherapy-Oncologic ProcedureChimera ProteinChimeric ProteinsChromosome 12ClinicalClinical ResearchClinical StudyClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsCombination Chemotherapy RegimenD12S1644DNA DamageDNA Damage RepairDNA Double Strand BreakDNA InjuryDNA RepairDNA Repair PathwayDNA ReplicationDNA SynthesisDNA biosynthesisDataDisease remissionDoseDrugsFamily memberFusion ProteinGamma-H2AXGene FusionGeneralized GrowthGenesGeneticGoalsGrowthHeadHigh Throughput AssayHistopathologyIL-4-STATIn VitroIn complete remissionIn vivo analysisInfantInvestigationInvestigational DrugsInvestigational New DrugsInvestigatorsLiverLocalized Fibrous TumorLocationLungLung Respiratory SystemMalignantMalignant - descriptorMalignant NeoplasmsMalignant Soft Tissue NeoplasmMalignant Solitary Fibrous TumorMalignant TumorMedical OncologistMedicationMeningesMesenchymal Cell NeoplasmMesenchymal Cell TumorMesenchymal NeoplasmMesenchymal TumorMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorModelingMolecularMolecular InteractionNeoplasm MetastasisNeovascularization InhibitorsNeuraxisOncogenesisOncologistOperative ProceduresOperative Surgical ProceduresPARP InhibitorPARP-1 inhibitorPARPiPDX modelPTK InhibitorsPathologicPathologistPathway interactionsPatient derived xenograftPatientsPharmaceutical PreparationsPhasePhenotypePoly(ADP-ribose) Polymerase InhibitorPoly(ADP-ribose) polymerase 1 inhibitorPrognosisProliferatingProtein Tyrosine Kinase InhibitorsQuimioterapiaRadiationRecurrenceRecurrentRemissionRepressionResearchResearch PersonnelResearchersResectedSTAT6STAT6 geneSTAT6BSTAT6CSYS-TXSafetySarcomaSecondary NeoplasmSecondary TumorSecureSoft tissue sarcomaSolitary Fibrous TumorSpainSpecificityStable DiseaseSurgicalSurgical InterventionsSurgical ProcedureSystemic TherapyTK InhibitorsTestingTissue GrowthTissue SampleTravelTumor CellTumor Cell LineTyrosine Kinase InhibitorUnscheduled DNA SynthesisVariantVariationadulthoodanti-tumor effectantiangiogenicantitumor effectbio-engineeredbio-engineersbio-markersbioengineeringbiologic markerbiological engineeringbiomarkerbonebromodomain extra-terminal inhibitorcancer chemotherapycancer metastasischemotherapycomplete responsedrug/agentgenome editinggenomic editinghemangiopericytomahepatic body systemhepatic organ systemhigh throughput screeninghigh-throughput drug screeningin vivoin vivo evaluationin vivo testinginhibitorinterleukin-4 Statmalignancymalignant phenotypemalignant soft tissue tumormeningemodel of animalneoplasm/cancerneoplastic cellnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyontogenypartial responsepathwaypatient derived xenograft modelpreventpreventingrepairrepairedresponsesuccesssurgerytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttumortumor cell metastasistumorigenesisvascularγH2AX
Description preview
Project Summary
Solitary fibrous tumor (SFT), historically also called hemangiopericytoma (HPC), is a soft-tissue sarcoma
occurring in adults and infants. This nonhereditary cancer is a result of an environmental intrachromosomal
gene fusion between NAB2 and STAT6 on chromosome 12, which fuses the activation domain of STAT6 with
the repression…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click